CliffBio
biologic

Afrezza

insulin human

Loss of exclusivityJune 2026projected — 12-year biologic exclusivity estimate
CompanyMannKind Corporation →View the full company profile on CliffBio

Drug detail

Brand nameAfrezza
Active ingredientinsulin human
Strength4UNITS/INH
Dosage formPowder
RouteInhalation
ModalityBiologic
FDA approvalJune 2014
Marketing statusRx

More from MannKind Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Afrezza patent cliff — loss of exclusivity June 2026 | CliffBio